EYD-001 (Takinib analog)
Rheumatoid Arthritis
Key Facts
About EydisBio
Founded in 2020 and based in Durham, North Carolina, EydisBio is a private biotech startup focused on addressing high unmet medical needs in autoimmunity and inflammation. The company's core innovation is its UPCP chemoproteomics platform, which enables the discovery of intrinsically selective kinase inhibitors, aiming to improve therapeutic outcomes and developmental success rates. Led by a founder with a successful track record of company creation and drug development, EydisBio is advancing its lead TAK1 inhibitor candidate through in vivo efficacy and pilot safety studies.
View full company profileAbout EydisBio
Founded in 2020 and based in Durham, North Carolina, EydisBio is a private biotech startup focused on addressing high unmet medical needs in autoimmunity and inflammation. The company's core innovation is its UPCP chemoproteomics platform, which enables the discovery of intrinsically selective kinase inhibitors, aiming to improve therapeutic outcomes and developmental success rates. Led by a founder with a successful track record of company creation and drug development, EydisBio is advancing its lead TAK1 inhibitor candidate through in vivo efficacy and pilot safety studies.
View full company profileAbout EydisBio
Founded in 2020 and based in Durham, North Carolina, EydisBio is a private biotech startup focused on addressing high unmet medical needs in autoimmunity and inflammation. The company's core innovation is its UPCP chemoproteomics platform, which enables the discovery of intrinsically selective kinase inhibitors, aiming to improve therapeutic outcomes and developmental success rates. Led by a founder with a successful track record of company creation and drug development, EydisBio is advancing its lead TAK1 inhibitor candidate through in vivo efficacy and pilot safety studies.
View full company profileAbout EydisBio
Founded in 2020 and based in Durham, North Carolina, EydisBio is a private biotech startup focused on addressing high unmet medical needs in autoimmunity and inflammation. The company's core innovation is its UPCP chemoproteomics platform, which enables the discovery of intrinsically selective kinase inhibitors, aiming to improve therapeutic outcomes and developmental success rates. Led by a founder with a successful track record of company creation and drug development, EydisBio is advancing its lead TAK1 inhibitor candidate through in vivo efficacy and pilot safety studies.
View full company profileAbout EydisBio
Founded in 2020 and based in Durham, North Carolina, EydisBio is a private biotech startup focused on addressing high unmet medical needs in autoimmunity and inflammation. The company's core innovation is its UPCP chemoproteomics platform, which enables the discovery of intrinsically selective kinase inhibitors, aiming to improve therapeutic outcomes and developmental success rates. Led by a founder with a successful track record of company creation and drug development, EydisBio is advancing its lead TAK1 inhibitor candidate through in vivo efficacy and pilot safety studies.
View full company profileOther Rheumatoid Arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase II/III |
| ERNA-201 | Eterna Therapeutics | Preclinical |
| Tc99m Tilmanocept | Navidea Biopharmaceuticals | Phase 2/3 |
| Monoclonal Antibody Biosimilar (Anti‑TNF) | USV Biologics Division | Phase 1 |
| Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure) | LFB | Pre-clinical |
| LFD-200 | Lifordi Immunotherapeutics | Phase 1 |
| MEV-N01 | Mesenbio | Pre-clinical |
| CIT-013 | Citryll | Phase 2a |
| Restem-L | Restem | Phase 2 |
| ASIT Platform | Ahead Therapeutics | Pre-clinical |
| AX-158 | Artax Biopharma | Phase 2 |